Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Depreciation and Depletion (2017 - 2025)

Marimed (MRMD) has disclosed Depreciation and Depletion for 10 consecutive years, with $2.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation and Depletion rose 16.67% to $2.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.2 million, a 10.81% increase, with the full-year FY2024 number at $7.9 million, up 43.64% from a year prior.
  • Depreciation and Depletion was $2.1 million for Q3 2025 at Marimed, roughly flat from $2.1 million in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $2.2 million in Q4 2024 to a low of $462000.0 in Q1 2021.
  • A 5-year average of $1.3 million and a median of $1.2 million in 2023 define the central range for Depreciation and Depletion.
  • Peak YoY movement for Depreciation and Depletion: soared 90.0% in 2024, then decreased 5.26% in 2025.
  • Marimed's Depreciation and Depletion stood at $601000.0 in 2021, then surged by 49.75% to $900000.0 in 2022, then soared by 88.89% to $1.7 million in 2023, then grew by 29.41% to $2.2 million in 2024, then decreased by 4.55% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Depreciation and Depletion are $2.1 million (Q3 2025), $2.1 million (Q2 2025), and $1.8 million (Q1 2025).